Buy GHK-Cu Peptide 50 mg Online | Copper Tripeptide-1 | Collagen, Wound Healing & Gene Expression Research | ≥99% Purity | CoA | SourceTides

Buy GHK-Cu Peptide 50 mg Online from SourceTides.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II) Complex; CAS 49557-75-7; also known as Copper Tripeptide-1) is a naturally occurring copper-binding tripeptide first isolated from human plasma by biochemist Loren Pickart in 1973.
It consists of three amino acids — glycine, histidine, and lysine — chelated to a copper(II) ion.
Despite its minimal size (MW 403.93 g/mol), GHK-Cu is one of the most biologically active endogenous peptides known: genome-wide expression profiling using the Broad Institute’s Connectivity Map demonstrated that GHK-Cu modulates the expression of over 4,000 human genes — approximately 31% of the human coding genome — at nanomolar concentrations.
This extraordinary genomic breadth covers collagen synthesis, extracellular matrix remodelling, wound healing, anti-inflammatory signalling, antioxidant defence, VEGF-driven angiogenesis, BDNF upregulation, anti-fibrotic activity, COPD lung repair, and anti-cancer gene expression patterns.
Plasma GHK concentration declines approximately 60% with age — from ~200 ng/mL at age 20 to ~80 ng/mL by age 60 — directly correlating with the decline in regenerative capacity, wound healing speed, and collagen synthesis that characterises biological ageing.
The 50 mg research vial format at SourceTides supports longer research protocols, repeat-dose studies, and multi-endpoint metabolomics panels without requiring frequent re-ordering.
Every SourceTides vial is lyophilised, tested at ≥99% HPLC purity, and ships with a full lot-specific Certificate of Analysis.
For in-vitro laboratory research use only. Not for human consumption.

GHK-Cu Peptide 50 mg — Technical Specifications

What Is GHK-Cu?

GHK-Cu is one of the most remarkable small molecules in biology. Three amino acids and a copper ion — yet it influences 4,000 genes, promotes tissue regeneration across at least six organ systems, and declines predictably with age in parallel with the biological ageing phenotype. No single peptide combines such molecular simplicity with such extraordinary regulatory reach.

The story begins in 1973. Loren Pickart, then at Stanford, was studying a longstanding paradox: old human liver tissue synthesised proteins less efficiently than young tissue, even when those cells were kept alive in the same culture conditions. Something in young human plasma was driving the difference. Pickart isolated the active factor — a tripeptide he identified as glycyl-L-histidyl-L-lysine. The peptide had one unusual property: it bound copper(II) with extraordinary affinity (association constant ~10¹⁵ M⁻¹ — among the highest of any known biological copper chelator). The copper-bound form was substantially more active than the free peptide. He named the complex GHK-Cu and spent the following five decades expanding its biology.

The 1980s established the wound healing and collagen biology. Maquart et al. (FEBS Lett. 1988) demonstrated that GHK-Cu at 1–10 nanomolar concentrations doubled collagen synthesis rates in human fibroblast cultures. This selectivity — active at concentrations comparable to the best pharmaceutical biologics, driving collagen specifically rather than all proteins — established GHK-Cu as a serious research compound rather than a crude extract.

The 2010s brought the genomics revolution to GHK-Cu. When the Broad Institute’s Connectivity Map was applied to GHK-Cu, the results were startling: the compound modulated expression of over 4,000 human genes — approximately one-third of the human genome. Gene sets that were upregulated included tissue remodelling, cell survival, mitochondrial function, antioxidant defence, VEGF-driven angiogenesis, and neurotrophic signalling. Gene sets that were downregulated included inflammatory cascades, fibrosis pathways, oncogene expression, and the expression profiles characteristic of COPD and other degenerative lung diseases. GHK-Cu’s gene expression pattern did not resemble any other known compound in the Connectivity Map database. When you buy GHK-Cu Peptide 50 mg from SourceTides, you access one of biology’s most extensively documented naturally-occurring regenerative compounds in a 50 mg research vial format designed for sustained multi-endpoint research programmes.

Why Copper? The Role of the Cu(II) Ion

The copper ion in GHK-Cu is not incidental. It is mechanistically essential, and understanding why illuminates the entire biology of this compound.

Copper is a trace element with two primary biological roles. As a redox catalyst in the Cu(I)/Cu(II) cycle, it participates in critical enzymatic reactions across the mitochondrial electron transport chain (cytochrome c oxidase, Complex IV), antioxidant defence (Cu/Zn-superoxide dismutase), collagen crosslinking (lysyl oxidase), neurotransmitter synthesis (dopamine β-hydroxylase), and iron metabolism (ceruloplasmin). As a signalling molecule, copper acts through copper-responsive transcription factors and copper chaperone proteins that regulate these enzyme systems.

Three critical copper-dependent enzymes are directly relevant to GHK-Cu’s biological activities. Lysyl oxidase (LOX) crosslinks nascent collagen and elastin fibrils by oxidising lysine residues — this crosslinking step converts soluble procollagen into the insoluble, mechanically stable collagen fibres that form the structural scaffold of connective tissue. Without lysyl oxidase activity, collagen is synthesised but never organised into functional tissue architecture. Cu/Zn-superoxide dismutase (SOD1) converts the superoxide radical (O₂⁻) to hydrogen peroxide (then further cleared by catalase and glutathione peroxidase) — the primary enzymatic first step in cellular antioxidant defence. Cytochrome c oxidase (Complex IV) is the terminal electron acceptor in the mitochondrial electron transport chain, transferring electrons from cytochrome c to molecular oxygen and thereby driving the proton gradient that synthesises ATP.

GHK serves as a high-affinity copper delivery system — a “copper chaperone” for these enzyme systems. By chelating Cu(II) and transporting it to cells in a bioavailable form, GHK-Cu provides the catalytic cofactor that all three of these enzyme families require for full activity. Free copper ions are toxic — they participate in Fenton chemistry, generating hydroxyl radicals that damage DNA, proteins, and lipid membranes. GHK-Cu delivers copper in a controlled, non-toxic chelated form that activates enzyme function without generating free-radical toxicity. This copper delivery function is distinct from the peptide’s direct gene expression effects and operates through a different mechanism.

How GHK-Cu Works — The Five Core Mechanisms

Mechanism 1 — Collagen and Extracellular Matrix Synthesis

The foundational GHK-Cu mechanism is direct stimulation of collagen synthesis in fibroblasts. Maquart et al. (1988; FEBS Lett; PMID: 3169264) demonstrated that GHK-Cu at nanomolar concentrations significantly increased collagen synthesis in human fibroblast cultures — selectively doubling collagen production relative to non-collagen protein synthesis. This selectivity for structural protein synthesis over general protein production is unusual and pharmacologically valuable. Subsequent work by Simeon et al. (2000; PMID: 11121126) confirmed that GHK-Cu also stimulates synthesis of glycosaminoglycans (dermatan sulfate, chondroitin sulfate) and the small proteoglycan decorin in wound tissue — the complete extracellular matrix package, not just collagen.

Critically, GHK-Cu achieves balanced matrix remodelling rather than simple excess deposition. It modulates matrix metalloproteinases (MMPs) and their inhibitors (TIMP-1, TIMP-2) simultaneously — allowing sufficient matrix breakdown to remove damaged tissue and prevent hypertrophic scarring while promoting new matrix synthesis. This MMP-TIMP balance explains why GHK-Cu-treated wounds tend to heal with flatter, less fibrotic scars and more normal tissue architecture than wounds treated with pro-collagen agents that stimulate synthesis without controlling degradation.

Mechanism 2 — Wound Healing Acceleration

GHK-Cu accelerates multiple phases of wound healing simultaneously. In the inflammatory phase, it reduces excessive cytokine production (TNF-α, IL-1β) while promoting the controlled inflammatory response needed to recruit repair cells. In the proliferative phase, it stimulates fibroblast migration and proliferation, endothelial cell migration and angiogenesis (VEGF upregulation), and keratinocyte migration for re-epithelialisation. In the remodelling phase, its collagen synthesis stimulation and MMP-TIMP balance produce organised, high-quality new extracellular matrix rather than disordered scar tissue.

GHK is encoded in the alpha-2(I) chain of Type I collagen at a specific recognition sequence. When proteases degrade collagen during tissue injury, they release GHK from this sequence into the wound environment — an elegant emergency response built directly into the structural protein that gets damaged. The released GHK-Cu then coordinates the repair response. This collagen-embedded GHK emergency release mechanism explains why GHK-Cu is particularly effective when used in wound research contexts where collagen breakdown is ongoing. It is not simply a growth factor — it is the tissue’s own injury-response coordinator.

Published animal data: GHK-Cu accelerated wound closure in rabbits, rats, mice, and pigs. Human clinical trial data: a 2023 IRB-approved trial (EurekAlert) reported 28% average increase in dermal collagen density after 3 months of topical GHK-Cu application in 21 women, with the top quartile showing 51% collagen increase. This represents one of the few human collagen increase results for any topical agent confirmed by objective measurement.

Mechanism 3 — Broad Gene Expression Modulation (4,000+ Genes)

The Connectivity Map analysis (Pickart & Margolina, Int J Mol Sci 2018; PMID: 29986520) revealed that GHK-Cu modulates approximately 4,000 human genes — about 31% of the protein-coding genome. The gene expression changes move systematically in the direction of restoring younger, healthier tissue states from aged or damaged baselines. Key upregulated gene clusters include: tissue remodelling enzymes (collagenases, MMPs, TIMPs); survival and anti-apoptotic genes (Bcl-2 family); mitochondrial function genes (cytochrome c oxidase subunits, ATP synthase); antioxidant enzyme genes (SOD1, SOD2, catalase, glutathione peroxidase); angiogenesis genes (VEGF, PECAM-1, angiopoietins); and neurotrophic factor genes (BDNF, NGF, NT-3). Key downregulated gene clusters include: inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, NF-κB targets); fibrosis pathways (TGF-β1, CTGF, fibronectin excess); cellular destruction pathways (caspases); and cancer-associated gene expression signatures (oncogenes including KRAS, MYC).

This systematic gene expression resetting — from aged/damaged patterns toward younger/healthier patterns — represents a fundamentally different mode of action from conventional single-target drugs. GHK-Cu does not block a specific receptor or inhibit a specific enzyme. It acts as a systems-level regulator of gene expression, shifting biological age-associated transcriptional patterns back toward youth. The Connectivity Map also revealed that GHK-Cu’s gene expression signature was unlike any other compound in the database — it did not match any known drug, hormone, or signalling molecule, indicating a novel mechanism.

Mechanism 4 — Antioxidant Defence and Copper Enzyme Activation

GHK-Cu upregulates expression of antioxidant enzyme genes (SOD1, SOD2, catalase, glutathione peroxidase) while simultaneously delivering bioavailable copper to activate Cu/Zn-SOD at the protein level. This dual transcriptional-plus-catalytic enhancement of antioxidant capacity operates through two independent channels: the copper delivery mechanism activates existing SOD1 enzyme immediately; the gene expression upregulation increases SOD1 protein production over days to weeks. The result is a sustained, amplified antioxidant response that exceeds what supplemental antioxidant molecules can achieve — because GHK-Cu enhances the cell’s own antioxidant machinery rather than delivering exogenous scavengers.

Mechanism 5 — COPD, Anti-Fibrotic, and Lung Repair Biology

One of the most striking applications of the Connectivity Map analysis was the discovery that GHK-Cu’s gene expression profile is the mirror image of the 127-gene emphysema/COPD signature. The genes upregulated in COPD are downregulated by GHK-Cu; the genes downregulated in COPD are upregulated by GHK-Cu. Subsequent laboratory confirmation (Pickart et al.) showed that GHK added to COPD lung fibroblasts restored actin cytoskeleton organisation, elevated integrin β1 expression, and improved collagen I contraction and remodelling — all markers of functional fibroblast restoration in damaged lung tissue. No human COPD trials have been completed for GHK-Cu, but the mechanistic foundation from gene expression analysis and in-vitro lung fibroblast studies is the most compelling preclinical case for any regenerative application of this compound.

GHK-Cu Research Evidence

GHK-Cu’s Decline With Age: The Research Basis for Ageing Applications

The age-related decline of GHK-Cu in human plasma is one of the most well-characterised molecular correlates of biological ageing. At age 20, plasma GHK concentration is approximately 200 ng/mL (roughly 600 nM — comfortably within the nanomolar active range confirmed in all mechanistic studies). By age 60, this has fallen to approximately 80 ng/mL (roughly 240 nM). By age 70–80, the decline continues further. This 60–70% age-related reduction directly correlates with the well-documented decline in wound healing speed, collagen synthesis rate, and tissue regenerative capacity that characterises normal ageing.

The mechanism of this decline is not fully characterised, but the consequences are well-documented: older individuals with lower plasma GHK have slower wound healing, thinner dermis, reduced collagen quality, and less efficient DNA repair. The Connectivity Map gene expression data shows GHK-Cu producing gene expression changes that systematically reverse the molecular signatures of ageing tissue — making GHK-Cu replacement (through topical or injectable routes) a well-motivated hypothesis in ageing and regenerative medicine research.

The 50 mg research vial format is particularly relevant here. Long-term biological ageing studies require extended treatment windows (4–12 weeks in rodents; months in larger models) and multiple tissue collection endpoints. The 50 mg format reduces costs and inter-batch variability in these extended protocols compared to multiple smaller vials. For researchers studying GHK-Cu alongside other longevity compounds — Epithalon, NAD⁺ Injectable, Thymalin — the 50 mg single-lot sourcing ensures consistent quality across the full protocol.

What Is GHK-Cu Used for in Research?

GHK-Cu Pharmacokinetics and Handling

GHK-Cu Quality Control at SourceTides

Every batch of GHK-Cu Peptide 50 mg from SourceTides passes the following tests. Copper content verification is the critical QC step unique to this compound — confirming that the active Cu(II) complex is present, not just the free GHK tripeptide.

GHK-Cu Regulatory Status

Peer-Reviewed References

Frequently Researched Alongside GHK-Cu

These compounds are the most common research partners for GHK-Cu across wound healing, tissue repair, longevity, and dermatology research protocols:

• BPC-157 — The most common tissue repair research partner for GHK-Cu; BPC-157 drives angiogenesis and repair via VEGFR2/NO/FAK, GHK-Cu drives collagen and ECM synthesis via copper-dependent metalloenzymes; complementary mechanisms covering the vascular and structural aspects of wound healing; studied together in combined repair protocols
• BPC-157 Capsules — Oral format of BPC-157 for GI and systemic repair research; studied alongside GHK-Cu in gut barrier, mucosal healing, and systemic tissue repair panels
• TB-500 (Thymosin Beta-4) — Actin cytoskeleton repair peptide; critical for cell migration in wound closure; studied with GHK-Cu in wound healing research combining actin-mediated cell migration (TB-500) and collagen matrix synthesis (GHK-Cu)
• Epithalon 10 mg — Khavinson telomerase activator; longevity; the most natural pairing in longevity research — Epithalon restores telomere biology and pineal function, GHK-Cu restores gene expression from aged to youthful patterns; together they represent cellular longevity (Epithalon) and systemic regenerative capacity (GHK-Cu)
• NAD⁺ Injectable — Sirtuin substrate; mitochondrial function; GHK-Cu upregulates mitochondrial function genes (cytochrome c oxidase, ATP synthase) that NAD⁺-driven SIRT3 also regulates; studied together in comprehensive mitochondrial ageing panels
• Thymalin 10 mg — Thymic immune bioregulator; studied alongside GHK-Cu in multi-system longevity and wound healing panels where immune restoration (Thymalin) and tissue regeneration (GHK-Cu) both decline with age
• Pinealon 10 mg — CNS antioxidant neuroprotection; SOD2/GPX1 upregulation; GHK-Cu upregulates SOD1/SOD2 via copper delivery and gene expression; studied together in antioxidant neuroprotection panels
• Sermorelin 10 mg — GHRH agonist; GH axis; GH drives IGF-1, which activates many of the same collagen and tissue repair pathways that GHK-Cu stimulates from the ECM level; studied together in tissue repair + GH axis research
• Ipamorelin 10 mg — Selective GHS-R1a agonist; clean GH pulse; studied with GHK-Cu in anti-ageing and skin regeneration protocols combining GH axis support (Ipamorelin) with direct ECM and collagen regeneration (GHK-Cu)
• Thymosin Alpha-1 — Immune modulation and antiviral; studied with GHK-Cu where the anti-inflammatory (GHK-Cu NF-κB suppression) and immune modulation (Thymosin Alpha-1) converge in wound healing and recovery biology
• Selank Amidate 10 mg — IL-6 suppression and GABAergic anxiolytic; GHK-Cu also downregulates IL-6 in inflammatory contexts; studied alongside Selank Amidate in neuroinflammation and skin-brain axis research
• LIPO-C Injectable — Lipotropic metabolic complex; methionine in LIPO-C feeds the methylation cycle and cysteine/glutathione production; glutathione is the primary intracellular antioxidant that works synergistically with GHK-Cu’s copper-mediated SOD activation for comprehensive antioxidant support

Frequently Asked Questions